Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID N BOWERS

Allopathic & Osteopathic Physicians Physical Medicine & Rehabilitation

NPI
1568494474
CMS profile
25793
Location
CHATTANOOGA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5,216.65

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID N BOWERS

NPI 1568494474 · CMS profile ID 25793

Allopathic & Osteopathic Physicians / Physical Medicine & Rehabilitation

CHATTANOOGA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568494474?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID N BOWERS, NPI 1568494474, CMS profile ID 25793. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568494474?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID N BOWERS, NPI 1568494474, CMS profile ID 25793. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568494474?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID N BOWERS, NPI 1568494474, CMS profile ID 25793, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1568494474?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $5,216.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
MERZ NORTH AMERICA, INC. $15.1501/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737045113 CMS
Allergan, Inc. $11.5701/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723549659 CMS
Flexion Therapeutics, Inc. $16.6001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752745447 CMS
Ipsen Biopharmaceuticals, Inc $1,950.0001/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741936901 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,162.38 80
PY2020 $5,216.65 54
PY2021 $1,608.59 45
PY2022 $7,832.45 45
PY2023 $7,006.46 41
PY2024 $539.72 31
PY2025 $516.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $31,971.20 111
PY2024 Principal investigator $4,071.60 4
PY2023 Principal investigator $63,292.80 52
PY2022 Principal investigator $60,850.00 46
PY2020 Principal investigator $4,012.50 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

111 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $5,240.00 10/17/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303761
Principal investigator 1 Ipsen Pharma SAS $1,440.00 10/17/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303763
Principal investigator 1 Ipsen Pharma SAS $61.20 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303739
Principal investigator 1 Ipsen Pharma SAS $62.40 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303741
Principal investigator 1 Ipsen Pharma SAS $176.40 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303743
Principal investigator 1 Ipsen Pharma SAS $171.60 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303745
Principal investigator 1 Ipsen Pharma SAS $192.00 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303747
Principal investigator 1 Ipsen Pharma SAS $26.40 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303749
Principal investigator 1 Ipsen Pharma SAS $144.00 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303751
Principal investigator 1 Ipsen Pharma SAS $157.20 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303753
Principal investigator 1 Ipsen Pharma SAS $49.20 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303755
Principal investigator 1 Ipsen Pharma SAS $61.20 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303757
Principal investigator 1 Ipsen Pharma SAS $90.00 03/19/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303759
Principal investigator 1 Ipsen Pharma SAS $1,454.40 02/07/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303681
Principal investigator 1 Ipsen Pharma SAS $1,191.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303481
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303483
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303485
Principal investigator 1 Ipsen Pharma SAS $1,245.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303487
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303489
Principal investigator 1 Ipsen Pharma SAS $114.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303491
Principal investigator 1 Ipsen Pharma SAS $1,245.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303493
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303495
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303497
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303499
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303501
Principal investigator 1 Ipsen Pharma SAS $57.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303503
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303505
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303507
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303509
Principal investigator 1 Ipsen Pharma SAS $1,122.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303511
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303513
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303515
Principal investigator 1 Ipsen Pharma SAS $57.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303517
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303519
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303521
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303523
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303525
Principal investigator 1 Ipsen Pharma SAS $391.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303527
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303529
Principal investigator 1 Ipsen Pharma SAS $1,245.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303531
Principal investigator 1 Ipsen Pharma SAS $1,122.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303533
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303535
Principal investigator 1 Ipsen Pharma SAS $315.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303537
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303539
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303541
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303543
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303545
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303547
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303549
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303551
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303553
Principal investigator 1 Ipsen Pharma SAS $1,122.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303555
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303557
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303559
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303561
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303563
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303565
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303567
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303569
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303571
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303573
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303575
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303577
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303579
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303581
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303583
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303585
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303587
Principal investigator 1 Ipsen Pharma SAS $157.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303589
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303591
Principal investigator 1 Ipsen Pharma SAS $114.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303593
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303595
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303597
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303599
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303601
Principal investigator 1 Ipsen Pharma SAS $171.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303603
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303605
Principal investigator 1 Ipsen Pharma SAS $57.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303607
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303609
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303611
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303675
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303677
Principal investigator 1 Ipsen Pharma SAS $57.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303679
Principal investigator 1 Ipsen Pharma SAS $391.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303683
Principal investigator 1 Ipsen Pharma SAS $49.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303685
Principal investigator 1 Ipsen Pharma SAS $1,122.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303687
Principal investigator 1 Ipsen Pharma SAS $1,184.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303689
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303691
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303693
Principal investigator 1 Ipsen Pharma SAS $114.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303695
Principal investigator 1 Ipsen Pharma SAS $243.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303697
Principal investigator 1 Ipsen Pharma SAS $1,183.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303699
Principal investigator 1 Ipsen Pharma SAS $186.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303701
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303703
Principal investigator 1 Ipsen Pharma SAS $1,183.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303705
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303707
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303709
Principal investigator 1 Ipsen Pharma SAS $171.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303711
Principal investigator 1 Ipsen Pharma SAS $57.60 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303713
Principal investigator 1 Ipsen Pharma SAS $114.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303715
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303717
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303719
Principal investigator 1 Ipsen Pharma SAS $176.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303721
Principal investigator 1 Ipsen Pharma SAS $192.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303723
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303725
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303727
Principal investigator 1 Ipsen Pharma SAS $90.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303729
Principal investigator 1 Ipsen Pharma SAS $61.20 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303731
Principal investigator 1 Ipsen Pharma SAS $62.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303733
Principal investigator 1 Ipsen Pharma SAS $26.40 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303735
Principal investigator 1 Ipsen Pharma SAS $144.00 02/03/2025 Non-covered Recipient Entity
Siskin Physical Medicine And Rehabilitation
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303737